Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

P2.15-24 Comparison of Pemetrexed Administered Q 3 Weeks vs Q 4 Weeks as Maintenance Therapy in NSCLC: Analysis of Real World Data From a Single Institution

Journal of Thoracic Oncology

English

P3.01-35 Outcomes in Advanced Non-Small Cell Lung Cancer After Discontinuation of PD-1 Checkpoint Inhibitor Due to Toxicity. A Retrospective Study

Journal of Thoracic Oncology

English

P3.04-14 TMB and Immune Checkpoint Inhibitor Gene Expression Are Unrelated in NSCLC Patients

Journal of Thoracic Oncology

English

P3.13-08 Assessment of EGFR Gene Mutations in Cf-Dna in Monitoring of Response to EGFR TKIs in Patients With Lung Adenocarcinoma

Journal of Thoracic Oncology

English

P2.09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma

Journal of Thoracic Oncology

English

MS28.05 Combining IO With Radiation

Journal of Thoracic Oncology

English

P3.01-109 Real-World Patient-Reported Outcome Assessment of Patients With Metastatic Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results From SWOG S1403

Journal of Thoracic Oncology

English

P2.01-102 Comprehensive Next-Generation Sequencing Guided Targeted Therapies Improve Clinical Outcomes of Lung Cancer Patients

Journal of Thoracic Oncology

English

MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications in Oncology

P2.15-24 Comparison of Pemetrexed Administered Q 3 Weeks vs Q 4 Weeks as Maintenance Therapy in NSCLC: Analysis of Real World Data From a Single Institution

P3.01-35 Outcomes in Advanced Non-Small Cell Lung Cancer After Discontinuation of PD-1 Checkpoint Inhibitor Due to Toxicity. A Retrospective Study

P3.04-14 TMB and Immune Checkpoint Inhibitor Gene Expression Are Unrelated in NSCLC Patients

P3.13-08 Assessment of EGFR Gene Mutations in Cf-Dna in Monitoring of Response to EGFR TKIs in Patients With Lung Adenocarcinoma

P2.09-01 Tumor-Associated Immune Cell Infiltration Patterns in Early Stage Squamous Lung Carcinoma

MS28.05 Combining IO With Radiation

P3.01-109 Real-World Patient-Reported Outcome Assessment of Patients With Metastatic Non-Small Cell Lung Cancer

OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results From SWOG S1403

P2.01-102 Comprehensive Next-Generation Sequencing Guided Targeted Therapies Improve Clinical Outcomes of Lung Cancer Patients

MA25.01 EORTC Lung Cancer Group Survey to Define Synchronous Oligometastatic Disease in NSCLC